The demographic, anthropometric, and laboratory characteristics of the subgroup cases were not significantly different from those of the cancer cases. Table 2. Anthropometric and laboratory characteristics of study subjects Mean serum hs-CRP selleck catalog level was significantly higher in subjects with metabolic syndrome (1.9 mg/L) than in those without metabolic syndrome (1.3 mg/L; P < 0.01, Wilcoxon rank-sum test). We also analyzed the association between hs-CRP and cancer according to the metabolic syndrome. The results are shown in Table Table3.3. After stratification, the positive associations persisted in subjects without metabolic syndrome. The adjusted ORs (model III) for cancer in subjects with metabolic syndrome were 1.51 (95% CI = 1.05�C2.17) in the second highest hs-CRP category and 2.

19 (95% CI =1.38�C3.45) in the highest hs-CRP category, as compared with the lowest category (P for trend = 0.0006). The adjusted ORs (model III) for cancer in subjects without metabolic syndrome were 1.04 (95% CI = 0.81�C1.34) in the second highest hs-CRP category and 1.92 (95% CI = 1.41�C2.63) in the highest hs-CRP category, as compared with the lowest category (P for trend = 0.0009). Table 3. Odds ratios (ORs) and 95% confidence intervals for cancer by serum hs-CRP category and metabolic syndrome status Overall, the prevalence ORs for cancer were positively associated with increasing categories of hs-CRP (<1, 1�C3, >3 mg/L). Crude and adjusted ORs for cancer are presented in Table Table4.4. The crude ORs for cancer were 1.36 (95% CI = 1.16�C1.62) for the second highest hs-CRP category and 2.

49 (95% CI = 2.02�C3.07) for the highest hs-CRP category, as compared with the lowest hs-CRP category (P for trend <0.0001). After adjustment for age, sex, BMI, abdominal obesity, diabetes, hypertension, dyslipidemia, aspirin use, smoking, alcohol consumption, exercise, education level, and income, the positive associations were weaker, but remained. The adjusted ORs for cancer were 1.16 (95% CI = 0.95�C1.42) for the second highest hs-CRP category and 1.94 (95% CI = 1.50�C2.50) for the highest hs-CRP category, as compared with the lowest hs-CRP category (P for trend <0.0001). The association was not attenuated after excluding cancer cases detected within 1 year of the health examination. These results are presented in Table Table44. Table 4.

Odds ratios (ORs) and 95% confidence intervals for cancer by serum hs-CRP category Subjects were stratified according to sex to assess the sex-specific association of hs-CRP and cancer. After stratification, as compared with the lowest hs-CRP category, the positive associations were stronger for women than for men in the second highest hs-CRP category and for men as compared with women in the highest hs-CRP category. The adjusted ORs (model III) for cancer in men were 1.15 (95% CI =0.90�C1.48) Entinostat in the second highest hs-CRP category and 2.15 (95% CI = 1.60�C2.